Cycloalkane-substituted pyrazoline derivatives, their...

Details Cycloalkane-substituted pyrazoline derivatives, their... Cycloalkane-substituted pyrazoline derivatives, their...

2011-08-09

2011-08-09

Young, Shawquia E (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S403000, C546S275400, C548S364100, C548S379400, C548S379700

Reexamination Certificate

active

07994200

ABSTRACT:
The present invention relates to Cycloalkane-substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

REFERENCES:
patent: 5017596 (1991-05-01), Colombo et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5849931 (1998-12-01), Frigola-Constansa et al.
patent: 6118009 (2000-09-01), Torrens-Jover et al.
patent: 6187930 (2001-02-01), Torrens-Jover et al.
patent: 6410582 (2002-06-01), Merce-Vidal et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 6956033 (2005-10-01), Ogawa et al.
patent: 2002/0058816 (2002-05-01), Kordik et al.
patent: 2002/0156104 (2002-10-01), Adams et al.
patent: 2003/0022925 (2003-01-01), Merce-Vidal et al.
patent: 2003/0153569 (2003-08-01), Adams et al.
patent: 2004/0092535 (2004-05-01), Barsanti et al.
patent: 2005/0137251 (2005-06-01), Garzon et al.
patent: 2005/0171179 (2005-08-01), Lange et al.
patent: 2005/0222138 (2005-10-01), Ohhata et al.
patent: 2005/0282798 (2005-12-01), Lazzari et al.
patent: 2006/0020010 (2006-01-01), Altisen et al.
patent: 2006/0052315 (2006-03-01), Leung et al.
patent: 2006/0106014 (2006-05-01), Boddupalli et al.
patent: 2006/0128673 (2006-06-01), Firnges et al.
patent: 2006/0172019 (2006-08-01), Ralston et al.
patent: 2006/0189658 (2006-08-01), Cuberes Altisen et al.
patent: 2006/0194843 (2006-08-01), Berdini et al.
patent: 1209326 (1970-10-01), None
patent: 02117605 (1988-10-01), None
patent: 8805046 (1988-07-01), None
patent: 8806583 (1988-09-01), None
patent: 9203421 (1992-03-01), None
patent: 0076503 (2000-12-01), None
patent: 01/70700 (2001-09-01), None
patent: 02080909 (2002-10-01), None
patent: 2004060882 (2004-07-01), None
patent: 2004078261 (2004-09-01), None
patent: 2005/077911 (2005-08-01), None
patent: WO2005074920 (2005-08-01), None
patent: 2006077414 (2006-07-01), None
patent: 2006077419 (2006-07-01), None
patent: 2006077425 (2006-07-01), None
patent: 2006077428 (2006-07-01), None
Vippagunta, et al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Dyck, et al., “Potent Imidazole and Triazole CB1 Receptor Antagonists Related to SR141716”, Bioorganic & Medicinal Chemistry Letters, 2004, pp. 1151-1154, vol. 14, Oxford, GB.
Chan et al.; “N-substituted Pyrazoline-type Insecticides”; ACS Symposium Series, No. 800, p. 144-155 (2002); Chem. Abstr. XP002335857.
Meier et al.; “Insecticidal Dihydropyrazoles with Reduced Lipophilicity”; ACS Symposium Series, No. 504, p. 313-326 (1992); Chem. Abstr. XP002335858.
Meyer et al.; “1,5-Diaryl-2, 3-pyrrolidinediones—Phenylhydrazine Derivatives”; Journal of Organic Chemistry, vol. 22, p. 1565-1567 (1957); Chem. Abstr. XP002335859.
International Search Report mailed Jul. 29, 2005 in International Application No. PCT/EP20058/001659.
Tamura, Kenji et al.; “One-Pot Synthesis of Trifluoroacetimidoyl Halides”; Journal of Organic Chemistry (1993), vol. 58, p. 32-38.
Hollister, Leo E.; “Health Aspects of Cannabis”; Pharmacological Reviews, vol. 38, No. 1, p. 1-20 (1986).
Murphy, L. et al.; Consroe and Sandyk; “Potential Role of Cannabinoids for Therapy of Neurological Disorders”; p. 459-524, CRC Press (1992).
Slavinska, V. et al.; “New Way for the Preparation of 4-Phenyl-2-Oxobutyric Acid Ethyl Ester”; Synthetic Communications, 26(11), p. 2229-2233 (1996).
Dujardin, G. et al.; “A Straightforward Route to E Aryl-a-oxobutenoic Esters by One-step Acid-catalysed Crotonisation of Pyruvates”; Synlett, No. 1, p. 147-149 (2001).
Pascual, Alfons; “Synthese des 5-[)Acetylhydrazono)-(4-chlorphenyl)-methyl]thiophen-2yl-esters der Trifluomethansulfonsaure”; J. Prakt. Chem. 341, No. 7, p. 695-700 (1999).
Lin, Shrong-Shi et al.; “Regioselective Friedel-Crafts Acylation with Unsymmetrically Substituted Furandicarboxylic Acid Anhydride and Furan Acid Chloride: Syntheses of 4-Substituted 3-Arylcarbonyl-2-Phenylfuran and 3-Substituted 4-Arylcarbonyl-2-Phenylfuran”; Heterocycles, vol. 55, No. 2, p. 265-277 (2001).
Rao, P.D. et al.; “Rational Syntheses of Porphyrins Bearing up to Four Different Meso Substituents”; J. Org. Chem., 65, p. 7323-7344 (2000).
Pearson, D.E. et al.; “Friedel-Crafts Acylations with Little or No Catalyst”; Synthesis, No. 10: October, p. 533-542 (1972).
Ross, Ruth A. et al.; “Agonist-Inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L-759633, L759656 and AM630”; British Journal of Pharmacology 126, p. 665-672 (1999).
Howlett, A.C. et al.; “International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors”; Pharmacological Reviews 54, p. 161-202 (2002).
Compton, David R. et al.; “In-Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Δ9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity”; The Journal of Pharmacology and Experimental Therapeutics, vol. 277, No. 2, p. 588-594 (1996).
Woolfe, G. et al.; “The Evaluation of the Analgesic Action of Pethidine Hydrochloride (Demerol)”; The Journal of Pharmacology and Experimental Therapeutics, vol. 80, p. 300-307 (1944).
Desmedt, L.K.C. et al.; “Anticonvulsive Properties of Cinnarizine and Flunarizine in Rats and Mice”; Arzneim Forsch (Drug Res.) 25, No. 9, p. 1408-1413 (1975).
Colombo, G. et al.; “Appetite Suppression and Weight Loss after teh cannabinoid Antagonist SR 141716”; Life Sciences, vol. 63, No. 8, p. PL 113-117 (1998).
Alpermann, H.G. et al.; “Pharmacological Effects of Hoe 249: A New Potential Antidepressant”; Drug Development Research, 25, p. 267-282 (1992).
Seth, R. et al.; “Chemistry and Pharmacology of Cannabis”; Progress in Drug Research, vol. 36, p. 71-115 (1991).
Muccioli, G.G. et al.; “CB1 and CB2 cannabinoid receptor antagonists and inverse agonists for obesity, metabolic syndrome and smoking cessation indications”; Expert Opinion on Therapeutic Patents, vol. 16, No. 10, p. 1405-1423 (2006).
Lange, J.H.M. et al.; “3,4-diarylpyrozolines as cannabinoid CB SUB 1 receptor antagonists with lower lipophilicity”; Bioorganic & Medicinal Chemistry Letters, vol. 15, No. 21, p. 4794-4798 (2005).
Thomas, B.F. et al.; “Long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide”; Bioorganic & Medicinal Chemistry, vol. 13, No. 18, p. 5463-5474 (2005).
Bryn et al.; (1999) Solid State Chemistry of Drugs; Source: SSCI Inc., Polymorphs, Chapter 10, 2nd edition, pp. 232-247.
Nimh; (Mar. 7, 2011) Eating Disorders; Source: http://www.nimh.nih.gov/health/publications/eating-disorders/complete-index.shtml.
Tonstad, S.; (2006) “Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors”; Source: Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, pp. 156-162.

Affiliated with

Also associated with

Rating

Cycloalkane-substituted pyrazoline derivatives, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cycloalkane-substituted pyrazoline derivatives, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkane-substituted pyrazoline derivatives, their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2691434